Abstract
Background The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) index, calculated as TG levels divided by HDL-C levels, is suggested as a predictor of cardiovascular disease (CVD). We investigated the association between the TG/HDL-C index and initial CVD events in high-risk patients with type 2 diabetes mellitus (T2DM).
Methods We analyzed the association between the TG/HDL-C index and CVD events in T2DM patients with retinopathy and hyperlipidemia without known CVD enrolled in the EMPATHY study, which compared intensive and standard statin therapy (targeting LDL-C levels <70 mg/dL and ≥100 to <120 mg/dL, respectively).
Results A total of 4665 patients were divided into high (TG/HDL-C ≥2.5, n=2013) and low (TG/HDL-C <2.5, n=2652) TG/HDL-C index groups. During a median follow-up of 36.8 months, 260 CVD events occurred. The high TG/HDL-C index group had higher CVD risk compared to the low TG/HDL-C index group (HR 1.89, 95% CI 1.45–2.47, p<0.001). This association was consistent across various subgroups. However, a trend toward interaction between the TG/HDL-C index and EMPATHY treatment allocation for CVD risk was observed (p for interaction=0.062). Intensive statin treatment was associated with reduced CVD risk compared to standard treatment in the high TG/HDL-C index group but not in the low group.
Conclusions A TG/HDL-C index ≥2.5 was associated with increased CVD risk in T2DM patients with retinopathy and hyperlipidemia without a history of CVD. The TG/HDL-C index may be a predictor of CVD and indicate patients who could benefit from intensive statin treatment.
Competing Interest Statement
K.S. reports grants from Daiichi Sankyo, Nippon Boehringer Ingelheim, and Otsuka Medical Devices. H.I. reports personal fees from SBI Pharmaceuticals, Wakunaga Pharmaceutical, NIPRO, Meiji, Taisho Pharmaceutical, Ono Pharmaceutical, Kowa, Takeda Pharmaceutical, Daiichi Sankyo, and Novartis Pharma. I.K. reports grant and/or personal fees from Idorsia Pharmaceuticals Japan, Daiichi Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, AstraZeneca, Kowa, MSD, Otsuka Pharmaceutical, Ono Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, and Bayer Yakuhin. H.T. reports grants and/or personal fees from Daiichi Sankyo, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Mitsubishi Tanabe Pharma, Teijin Pharma, Nippon Boehringer Ingelheim, AstraZeneca, Ono Pharmaceutical, Kowa, IQVIA Service Japan, MEDINET, Medical Innovation Kyushu, Bayer Yakuhin, Johnson & Johnson, NEC, Nippon Rinsho and Japanese Heart Failure Society. K.A. received grants from Mochida Pharmaceutical and Actelion Pharmaceuticals Japan. Other authors report no conflicts of interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethical committee of Kyushu University (No. 2020-445).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are not publicly available due to ethical restrictions but are available from the corresponding author on reasonable request.
Non-standard Abbreviations and Acronyms
- ACEI
- angiotensin converting enzyme inhibitor
- ARB
- angiotensin II receptor blocker
- BMI
- body mass index
- BP
- blood pressure
- CCB
- calcium channel blocker
- CVD
- cardiovascular disease
- eGFR
- estimated glomerular filtration rate
- HbA1c
- hemoglobin A1c
- HDL-C
- high density lipoprotein cholesterol
- LDL-C
- low density lipoprotein cholesterol
- T2DM
- type 2 diabetes mellitus
- TG
- triglyceride
